Bora Pharmaceuticals Co., LTD.

6472

TW0006472004

Pharmaceuticals

End-of-day quote Taiwan S.E. Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
768 ^TWD	+0.52%		+5.49%	+20.19%

14/05	Bora Pharmaceuticals USA Inc. announced that it expects to receive $57 million in funding from Bora Pharmaceuticals Co., LTD.	CI
12/04	Bora Pharmaceuticals Co., LTD. agreed to acquire remaining 34.3% stake in Bora Biologics Co., Ltd.	CI

Bora Pharmaceuticals Co., Ltd. Announces Appointment of Sustainable Development Committee Members

March 09, 2022 at 02:34 pm IST

Bora Pharmaceuticals Co., LTD. announced the Company set up the Sustainable Development Committee and its committee member. Name and resume of the new position holder: Sheng Pao-Shi/The Company's chairman; Chen Shih-Min/The Company's director; Lee Yi-Chin/The Company's independent director. Effective date of the new member is March 09, 2022.

Latest news about Bora Pharmaceuticals Co., LTD.

Bora Pharmaceuticals USA Inc. announced that it expects to receive $57 million in funding from Bora Pharmaceuticals Co., LTD.	14/05	CI
Bora Pharmaceuticals Co., LTD. agreed to acquire remaining 34.3% stake in Bora Biologics Co., Ltd.	12/04	CI
Bora Pharmaceuticals Co., LTD. completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd..	01/04	CI
Bora Pharmaceuticals USA Inc. announced that it expects to receive $1 billion in funding from Bora Pharmaceuticals Co., LTD.	29/03	CI
Bora Pharmaceuticals Co., LTD. announces an Equity Buyback for 1,000,000 shares, representing 0.99% for TWD 6,832.17 million.	07/03	CI
Bora Pharmaceuticals Co., LTD. Announces Cash Dividend for Second Half of 2023	07/03	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Bora Pharmaceuticals Co., LTD. authorizes a Buyback Plan.	07/03	CI
Bora Pharmaceuticals USA Inc. announced that it expects to receive $100 million in funding from Bora Pharmaceuticals Co., LTD.	07/03	CI
Bora Pharmaceuticals Co., LTD.(TWSE:6472) added to Taiwan TAIEX Index	22/01	CI
Bora Pharmaceuticals Co., LTD. agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. for approximately $210 million.	16/01	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
SunWay Biotech Co., LTD. agreed to acquire Bora Health Inc from Bora Pharmaceuticals Co., LTD..	21/23/21	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Bora Pharmaceuticals Co., Ltd. Elects Lin Hsin-I as Independent Director	06/23/06	CI
Bora Pharmaceuticals Co., Ltd. Announces Cash Dividend, Payable on July 28, 2023	05/23/05	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Bora Pharmaceuticals Co., LTD. Announces Contract Signing of the Syndicated Loan with Syndicate Bank	21/22/21	CI
Bora Pharmaceuticals Co., LTD. completed the acquisition of TWi Pharmaceuticals, Inc.	01/22/01	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Bora Pharmaceuticals Co., LTD. Announces Common Stock Cash Dividend, Payable on August 2, 2022	22/22/22	CI
Bora Pharmaceuticals Co., LTD. announced that it has received TWD 800 million in funding	14/22/14	CI
Bora Pharmaceuticals Co., LTD. agreed to acquire TWi Pharmaceuticals, Inc.	14/22/14	CI

Chart Bora Pharmaceuticals Co., LTD.

Duration

Period

More charts

Company Profile

Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.

Sector

Pharmaceuticals

Calendar

27/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Bora Pharmaceuticals Co., LTD.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

768 TWD

Average target price

894.4 TWD

Spread / Average Target

+16.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BORA PHARMACEUTICALS CO., LTD.	+20.19%	238.4Cr
ELI LILLY AND COMPANY	+39.73%	72TCr
NOVO NORDISK A/S	+34.28%	59TCr
JOHNSON & JOHNSON	-4.06%	37TCr
MERCK & CO., INC.	+20.36%	33TCr
ABBVIE INC.	+2.95%	28TCr
ASTRAZENECA PLC	+17.02%	24TCr
NOVARTIS AG	+9.31%	21TCr
ROCHE HOLDING AG	-5.07%	21TCr
PFIZER, INC.	+0.03%	17TCr

Other Pharmaceuticals